Hattersheim (ots) – CIDP, chronic inflammatory demyelinating polyneuropathy, is a rare autoimmune disease in which the insulating layer of the nerve fibers is attacked, inflamed and gradually broken down. The result: a disturbance in the signal transmission in the nerves. This leads to impairments in movement and sensory perception. It is caused by the patient’s own immune system, which can no longer reliably differentiate between “own” and “foreign” in the case of an autoimmune disease and which also wrongly destroys the body’s own cells.
A disease with many faces
CIDP is a complex disease. The symptoms can vary significantly. They develop either slowly and over a longer period of time or in batches of different intensities. Therefore, CIDP is often diagnosed late or not correctly at all.
A distinction is made between motor and sensory symptoms, depending on whether motor (responsible for movement) or sensory (responsible for perception) nerve fibers are affected.
The motor symptoms include reduced strength and mobility, or gait insecurity. The CIDP often shows in the beginning in a bilateral weakness in the legs or arms. What starts with a slight muscle weakness can lead to symptoms of paralysis. Sensory symptoms appear e.g. in the form of sensory disturbances on the hands and feet or changed perception of touch.
Early diagnosis is crucial
If polyneuropathy is suspected, the patient should be referred to a neurologist for an early diagnosis. In the course of further investigations, e.g. B. other neurological autoimmune diseases such as Guillain-Barré syndrome (acute form of CIDP) excluded. Diabetes and alcohol abuse can also lead to chronic polyneuropathy and are therefore often wrongly assumed to be the cause. Appropriate treatment can be initiated once a CIDP has been diagnosed.
My life with CIDP
In their very personal stories on the service portal https://www.leben-mit-cidp.de?utm_source=Focus&utm_medium=nativeads & utm_campaign = awarness, they tell how patients deal with their illness and lead a self-determined life despite CIDP. Here, patients, relatives and other interested parties can find further useful information on illness, diagnosis, treatment options and other services.
About CSL Behring
CSL Behring (https://cslbehring.com/) is a global leader in biotherapeutics that is committed to its promise to save lives. We focus entirely on the needs of our patients. We develop innovative therapeutic agents for the treatment of blood coagulation disorders, primary immune disorders, hereditary angioedema, congenital respiratory diseases and neurological diseases and manufacture products for this using the latest technologies.
The products of our company are also used in cardiac surgery, organ transplants, in the treatment of burns and in the prevention of hemolytic disease in the newborn.
With CSL Plasma, CSL Behring operates one of the world’s largest plasma extraction networks. The parent company, CSL Limited (https://www.csl.com/) (ASX: CSL; USOTC: CSLLY), is headquartered in Melbourne, Australia, employs over 25,000 people and delivers life-saving therapeutics to people in over 70 countries . Read inspiring stories about the promise of biotechnology at CSLBehring.com/Vita (https://www.cslbehring.com/vita), or follow us on Twitter.com/CSL (https://twitter.com/csl) . You can find more information at https://www.cslbehring.ch/ and https://www.cslbehring.de/
Reprint free of charge / voucher requested
Further material: https://www.presseportal.de/pm/82137/4609120 OTS: CSL Behring GmbH
Original content by: CSL Behring GmbH, transmitted by news aktuell
Press portal newsroom: CSL Behring GmbH